RT Journal Article
SR Electronic
T1 Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3563
OP 3568
DO 10.21873/invivo.12659
VO 35
IS 6
A1 IKKO TOMISAKI
A1 MIRII HARADA
A1 KEI TOKUTSU
A1 AKINORI MINATO
A1 YUJIRO NAGATA
A1 RIEKO KIMURO
A1 MASAHIRO MATSUMOTO
A1 NAOHIRO FUJIMOTO
YR 2021
UL http://iv.iiarjournals.org/content/35/6/3563.abstract
AB Background/Aim: To clarify the clinical significance of the temporary elevated C-reactive protein (CRP) levels followed by a decrease below baseline (CRP flare response) after administration of pembrolizumab to patients with advanced urothelial carcinoma (UC). Patients and Methods: We retrospectively reviewed 31 patients with advanced UC who received pembrolizumab. Patients were categorized into 3 groups (flare-responder, responder, non-responder) according to early CRP kinetics. Intergroup tumor response and survivals were compared. Results: Objective response rates of flare-responder, responder, and non-responder groups were 75%, 80%, and 26%, respectively. Median overall survival was not reached in flare-responder and responder groups, and was 10.2 months in the non-responder group (p=0.03). Furthermore, the flare-responder group did not reach median progression-free survival, and for the responder and non-responder groups it was 15.2 and 2.8 months, respectively (p=0.03). Conclusion: CRP flare response might be a promising biomarker in patients with advanced UC who received pembrolizumab.